The Role of Neoantigens in Cancer Immunotherapy

Area of Science:

• Oncology
• Immunology
• Bioinformatics

Background:

• Somatic mutation-derived neoantigens are tumor-specific, potentially eliciting potent antitumor T-cell responses.
• Minimal immune tolerance associated with neoantigens enhances their therapeutic potential in cancer immunotherapy.
• Neoantigens are primarily identified using bioinformatics approaches, notably whole-exome sequencing.

Purpose of the Study:

• To review the historical context of neoantigen-driven tumor control.
• To introduce contemporary methods for neoantigen screening and identification.
• To discuss the pivotal role of neoantigens in advancing cancer immunotherapies.

Main Methods:

• Literature review of neoantigen research.
• Analysis of bioinformatics technologies for neoantigen identification (e.g., whole-exome sequencing).
• Examination of clinical data from personalized cancer vaccines and adoptive T-cell therapies.

Main Results:

• Neoantigen-targeted therapies, including personalized vaccines and T-cell therapies, demonstrate promising clinical outcomes.
• Advancements in bioinformatics have significantly improved the accuracy and efficiency of neoantigen discovery.
• Neoantigens represent a key frontier in developing effective cancer immunotherapies.

Conclusions:

• Targeting neoantigens offers a promising strategy for cancer treatment due to their tumor-specific nature and immunogenicity.
• Personalized neoantigen-based therapies are advancing rapidly, showing significant therapeutic potential.
• Overcoming challenges in neoantigen identification and targeting is crucial for realizing their full clinical impact.